Who owns Coya Therapeutics, Inc. (COYA)? Elite investor 13F holders
2 tracked elite investors reported holding Coya Therapeutics, Inc as of 2026-06-30, including Greenlight Capital, Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
2 tracked investors currently reported holding · Latest report period: 2026-06-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Greenlight Capital | COYA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-14 00:00:00 | 13662909.00 USD | 2335540.000000 | Shares | hold | Original filing |
| Renaissance Technologies LLC | COYA THERAPEUTICS INC | SHARE | 2026-06-30 | 2026-08-13 00:00:00 | 1128968.00 USD | 192986.000000 | Shares | add | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.